Cited by 878Influenza Virus Research StudiesRespiratory viral infections researchBacterial Infections and Vaccines

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

Open access

DiazGranados, Carlos A., Dunning, Andrew J., Kimmel, Murray, Kirby, Daniel, Treanor, John, Collins, Avi, Pollak, Richard, Christoff, Janet, Earl, John, Landolfi, Victoria, Martin, Earl, Gurunathan, Sanjay, Nathan, Richard, Greenberg, David P., Tornieporth, Nadia G., Decker, Michael D., Talbot, H. Keipp·2014·New England Journal of Medicine

DOI 10.1056/nejmoa1315727

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: As compared with a standard-dose vaccine, a high-dose, trivalent, inactivated influenza vaccine (IIV3-HD) improves antibody responses to influenza among adults 65 years of age or older. This study evaluated whether IIV3-HD also improves protection against laboratory-confirmed influenza illness. METHODS: We conducted a phase IIIb-IV, multicenter, randomized, double-blind, active-controlled trial to compare IIV3-HD (60 μg of hemagglutinin per strain) with standard-dose trivalent, inactivated influenza vaccine (IIV3-SD [15 μg of hemagglutinin per strain]) in adults 65 years of age or older. Assessments of relative efficacy, effectiveness, safety (serious adverse events), and immunogenicity (hemagglutination-inhibition [HAI] titers) were performed during the 2011-2012 (year 1) and the 2012-2013 (year 2) northern-hemisphere influenza seasons. RESULTS: A total of 31,989 participants were enrolled from 126 research centers in the United States and Canada (15,991 were randomly assigned to receive IIV3-HD, and 15,998 to receive IIV3-SD). In the intention-to-treat analysis, 228 participants in the IIV3-HD group (1.4%) and 301 participants in the IIV3-SD group (1.9%) had laboratory-confirmed influenza caused by any viral type or subtype associated with a protocol-defined influenza-like illness (relative efficacy, 24.2%; 95% confidence interval [CI], 9.7 to 36.5). At least one serious adverse event during the safety surveillance period was reported by 1323 (8.3%) of the participants in the IIV3-HD group, as compared with 1442 (9.0%) of the participants in the IIV3-SD group (relative risk, 0.92; 95% CI, 0.85 to 0.99). After vaccination, HAI titers and seroprotection rates (the percentage of participants with HAI titers ≥ 1:40) were significantly higher in the IIV3-HD group. Conclusions: Among persons 65 years of age or older, IIV3-HD induced significantly higher antibody responses and provided better protection against laboratory-confirmed influenza illness than did IIV3-SD. (Funded by Sanofi Pasteur; ClinicalTrials.gov number, NCT01427309.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa1315727

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Fiore, A. E., Shay, D. K., Broder, K. R., Iskander, J. K., Uyeki, T. M., Mootrey, G., Bresee, J. S., & Cox, N. S. (2001) · PsycEXTRA Dataset · doi:10.1037/e548312006-001 · Cited by 5,006
Mortality Associated With Influenza and Respiratory Syncytial Virus in the United States
Thompson, W. W., Shay, D. K., Weintraub, E., Brammer, L., Cox, N., Anderson, L. J., & Fukuda, K. (2003) · JAMA · doi:10.1001/jama.289.2.179 · Cited by 3,673
Influenza-Associated Hospitalizations in the United States
Thompson, W. W. (2004) · JAMA · doi:10.1001/jama.292.11.1333 · Cited by 2,213
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
Fiore, A. E., Uyeki, T. M., Broder, K. R., Finelli, L., Euler, G. L., Singleton, J. A., Iskander, J. K., Wortley, P. M., Shay, D. K., Bresee, J., et al. (2009) · PubMed · Cited by 1,964
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100
The Efficacy of Influenza Vaccination in Elderly Individuals
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 883
Impact of Influenza Vaccination on Seasonal Mortality in the US Elderly Population
Simonsen, L., Reichert, T. A., Viboud, C. G., Blackwelder, W. C., Taylor, R. J., & Miller, M. A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.265 · Cited by 541
Randomized, Double‐Blind Controlled Phase 3 Trial Comparing the Immunogenicity of High‐Dose and Standard‐Dose Influenza Vaccine in Adults 65 Years of Age and Older
Falsey, A. R., Treanor, J. J., Tornieporth, N., Capellan, J., & Gorse, G. J. (2009) · The Journal of Infectious Diseases · doi:10.1086/599790 · Cited by 388
Self-citation
Influenza Activity — United States, 2015–16 Season and Composition of the 2016–17 Influenza Vaccine
Davlin, S. L., Blanton, L., Kniss, K. L., Mustaquim, D., Smith, S., Kramer, N. A., Cohen, J., Cummings, C. N., Garg, S., Flannery, B. L., et al. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6522a3 · Cited by 328

Show all 29 references

Research works printed but not linked: 7

Fiore AE, 2010, MMWR Recomm Rep, 59, 1
Praditsuwan R, 2005, J Med Assoc Thai, 88, 256
10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I · DOI · Paper page
2012, MMWR Morb Mortal Wkly Rep, 61, 414
2013, MMWR Morb Mortal Wkly Rep, 62, 997
2013, MMWR Morb Mortal Wkly Rep, 62, 473
2013, Wkly Epidemiol Rec, 88, 101

Sorted by citations

Items 801–878 of 878

High-dose influenza vaccine for elderly: a closer look into the real-world data
Colombo, L., Steinberg, A. E., & Hadigal, S. (2025) · Current Medical Research and Opinion · doi:10.1080/03007995.2025.2559871
Identifying plausible ranges for differential vaccine efficacy across high- and low-income settings: A Systematic Review, Descriptive Meta-Analysis, and illustrative evidence analysis.
Katama, E. N., Gallagher, K. E., Shah, A. S. V., Nokes, D. J., & McAllister, D. (2025) · Wellcome Open Research · doi:10.12688/wellcomeopenres.24913.1
Modelling the Impact on Greenhouse Gas Emissions From Using a High Dose Compared With a Standard Dose Influenza Vaccine in Adults Aged 65 Years and Older in FrancePreprint
Allard, L., Bricout, H., de Fougerolles, T. R., Crépey, P., Loubet, P., Thébaut, J.-F., Cabelguenne, D., Lévy, P., Man, S. D., & de la Tour, P. (2025) · Research Square · doi:10.21203/rs.3.rs-7470484/v1
Efficacy and Safety of Influenza and COVID-19 Vaccines
Kawai, N., Ikematsu, H., & Bando, T. (2025) · Kansenshogaku zasshi · doi:10.11150/kansenshogakuzasshi.r25001
Seasonal Influenza Vaccination
Riccio, M. D., & Maggi, S. (2025) · Springer eBooks · doi:10.1007/978-3-032-04020-6_13
High‐Dose vs. Standard‐Dose Influenza Vaccine in Older Patients With Hypertension: A Post Hoc Analysis of DANFLU‐1
Langhoff, A. C. F., Johansen, N. D., Modin, D., Janstrup, K. H., Bartholdy, K. V., Espersen, C., Nealon, J., Samson, S., Loiacono, M. M., Harris, R. C., et al. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70177
Comparing uptake of high-dose and standard-dose influenza vaccination at the practice and patient level in Germany
Meyer, A. C., Braegelmann, K., Orozco-Ruiz, X., Kruppert, S., & Damm, O. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.128075
Empfehlungen für die Impfung Erwachsener für Pneumologen
Ewig, S., Hinze, C. A., Vogelmaier, C., Stierl, M., & Rademacher, J. (2025) · Pneumologie · doi:10.1055/a-2732-6651
Current and Emerging Approaches to Evaluating Influenza Vaccine Performance
Neuzil, K. M. (2025) · New England Journal of Medicine · doi:10.1056/nejme2513191
Current Influenza Vaccine Options for 2014
Torbic, H., & Roach, E. M. (2015) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-015-0077-7
Additional file 1 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735507
Additional file 2 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735510
Additional file 2 of Independence estimators for re-randomisation trials in multi-episode settings: a simulation study
Kahan, B. C., White, I. R., Eldridge, S. M., & Hooper, R. (2021) · Figshare · doi:10.6084/m9.figshare.16909549
Additional file 4 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735516
Additional file 3 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735513
Additional file 7 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735525
Additional file 8 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735528
Additional file 1 of The impact of circadian rhythms on the immune response to influenza vaccination in middle-aged and older adults (IMPROVE): a randomised controlled trial
Liu, Y., Zhang, H., Yuan, G., Yao, M., Li, B., Chen, J., Fan, Y., Mo, R., Lai, F., Chen, X., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21351406
Additional file 6 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735522
Additional file 1 of Independence estimators for re-randomisation trials in multi-episode settings: a simulation study
Kahan, B. C., White, I. R., Eldridge, S. M., & Hooper, R. (2021) · Figshare · doi:10.6084/m9.figshare.16909546
Additional file 1 of Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives
de Fougerolles, T. R., Baïssas, T., Perquier, G., Vitoux, O., Crépey, P., Bartelt-Hofer, J., Bricout, H., & Petitjean, A. (2024) · Figshare · doi:10.6084/m9.figshare.25750038
Additional file 5 of The effect of metformin on influenza vaccine responses in nondiabetic older adults: a pilot trial
Martin, D. E., Cadar, A. N., Panier, H. A., Torrance, B. L., Kuchel, G. A., & Bartley, J. M. (2023) · Figshare · doi:10.6084/m9.figshare.22735519
Shifting Perspective in Influenza Vaccines Efficacy: How Risk Difference Shows an Alternative View of the Comparative Efficacy Profile of Newer and Enhanced Influenza Vaccines Compared to Standard, Egg-Based Vaccines
Colombo, L., Palache, A. M., & Hadigal, S. (2026) · Vaccines · doi:10.3390/vaccines14010108
Dual impact of squalene-adjuvanted influenza vaccine on immunity and glucose homeostasis in obese mice
Ahn, S. Y., Jo, S.-M., Ho, T. L., Kang, I., & Ko, E. (2026) · Scientific Reports · doi:10.1038/s41598-026-35917-4
Vaccination des seniors : un impératif de santé publique au défi de l’immunosénescence
Lelièvre, P. J.-D. (2026) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(26)76564-3
Cost-effectiveness of routine influenza vaccination program for individuals aged 65 years and older in Japan: Substituting standard-dose inactivated vaccine with high-dose inactivated vaccine
Hoshi, S., Seposo, X., & Kondo, M. (2026) · IJID Regions · doi:10.1016/j.ijregi.2026.100858
Die passende Influenzavakzine: Schlägt die Hochdosis die Standarddosis?
Gillissen, A. (2026) · Pneumo News · doi:10.1007/s15033-026-4277-5
From methods to policy: a critical appraisal of the 2024 ECDC guidance on enhanced influenza vaccines
de Lejarazu, R. O., Ocaña, D., Arrazola, P., Orrico‐Sánchez, A., Redondo, E., Sanz-Muñoz, I., Tolosa, N., & Trilla, A. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1760791
Cytomegalovirus serostatus and plasma MCP-1 levels are associated with antibody response to seasonal influenza vaccine across age and sexPreprint
Ratishvili, T., Haralambieva, I. H., Goergen, K. M., Ovsyannikova, I. G., Pickering, H. C., Pellegrini, M. A., Cappelletti, M., Reed, E. F., Poland, G. A., & Kennedy, R. B. (2026) · medRxiv · doi:10.64898/2026.03.15.26348451
Vaccines Against Pneumonia
Renzetti, M., & Losier, A. (2026) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2025.12.019
Clinical Effectiveness of High-Dose versus Standard-Dose Influenza Vaccines in Older Adults: A Systematic Review And Meta-Analysis of Randomized Controlled Trials
Watanabe, S., Orii, R., Osada, R., Kaneko, M., & Yumoto, K. (2026) · Journal of Clinical Question · doi:10.69854/jcq.2026.0008
Human broadly neutralizing influenza B virus antibodies recognizing hemagglutinin computationally optimized broadly reactive antigens
Mota, Y. C., Dzimianski, J. V., Lopez, M., Richardson, R. A., Ross, T. M., Kunkel, I., O’Rourke, S. M., Serrão, V. H. B., DuBois, R. M., & Sautto, G. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1747235
Cost-effectiveness analysis of influenza vaccination with a high-dose vaccine versus an adjuvanted quadrivalent vaccine in older adults in SpainPreprint
Abellán, J., Redondo, E., de Miguel, Á. G., Muñoz, I. S., Diaz-Aguiló, A., Palomo, P., Farré, M., Callejo, D., Pinel, M., & López-Belmonte, J. L. (2026) · medRxiv · doi:10.64898/2026.03.23.26349057
Caractérisation moléculaire du domaine de liaison à l'ARN de la protéine non-structurale 1 (NS1) des virus influenza A lors de l'interaction avec un ARN double-brin de haute affinité contenant des séquences sélectionnées in vitro
Wacquiez, A. (2020) · theses.fr (ABES) · doi:10.70675/8b88f11ez1daaz4387z9531z0dbc55b3ec14
Cost-effectiveness of vaccination of older adults with an MF59®-adjuvanted quadrivalent influenza vaccine compared to standard-dose and high-dose vaccines in South Korea and Taiwan
Hsieh, S., Choi, M. J., Chen, Y.-C., Cheng, S., Liu, D.-P., Song, J. Y., Tang, X., Mould-Quevedo, J. F., Cheong, H. J., & Chang, C.-J. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128533
Influenza vaccine-specific CD4+ T cell responses are impaired in older adults
Saint-Charles, P., Hagen, M., Autaa, G., Bijvank, E., Beckers, L., van Beek, J., van Baarle, D., Weinberger, B., & Appay, V. (2026) · npj Vaccines · doi:10.1038/s41541-026-01437-5
Immune Ageing: From Cellular Remodelling To Clinical Outcomes
Kashyap, D. (2026) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.16.7s.104
Comparative Effectiveness of High‐Dose and Standard‐Dose Influenza Vaccines for Hospitalisation and Mortality in Adults Aged 65 and Older: An Updated Systematic Review and Meta‐Analysis
Khan, B. W., Khattak, M. H., Amjad, M. M., Siddiqui, S. A., Qazi, T. I., Rehmat, H., Khan, M. F., Khan, H. W., Mian, A. M., Ullah, M., et al. (2026) · Reviews in Medical Virology · doi:10.1002/rmv.70158
CD25+ cell depletion enhances protective immunity of PR8 inactivated influenza vaccine in aged mice
Zhang, Y. G., Liu, L., Chen, T., Li, M., Shi, X., & Liu, Y. (2026) · Virology · doi:10.1016/j.virol.2026.110938
Real-World Safety Profile of an Indian Trivalent Influenza Vaccine: Results From a Multi-centre Post-marketing Surveillance Study
Singhvi, A. S., Manglik, A. K., Mukhopadhyay, B., Annamalai, C. K., Bhide, M., Sankharva, N. N., Adlakha, N., Sharma, S. K., Verma, A. K., Dutta, T., et al. (2026) · Cureus · doi:10.7759/cureus.108396
Cost-Effectiveness Analysis of the High-Dose Trivalent Influenza Vaccine in the Elderly Population in Italy
Panatto, D., Bellone, M., Castello, L., Zanetta, L., & Piccolo, A. (2026) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s588333
Older adults bear the burden: risk factors for severe influenza outcomes among hospitalized adults in a 9-season multicenter active surveillance study
Özışık, L., Tanrıöver, M. D., Ozdede, M., Bösi, A. T. B., Cakir, B., Badur, S., Puig‐Barberà, J., Akçay, M., Unal, S., & GIHSN Türkiye Study Group (2026) · Medicine · doi:10.1097/md.0000000000048625
Vaccine Effectiveness Estimates Against Influenza A(H3N2)-Associated Hospitalized Severe Acute Respiratory Infections in Beijing, China, 2025/26 Influenza Season
Ma, C., Zhang, J., Ma, J., Duan, W., Wang, Y. F., Hu, X., Li, J., Zhang, L., Di, Y., Yan, S., et al. (2026) · Vaccines · doi:10.3390/vaccines14050457
Cost-effectiveness of free influenza vaccination policy for Chinese older adults: a modeling analysis using real-world data
Wu, X., Tao, Y., Sun, Y., Chen, J. P., Lv, M., Yang, T., & Ye, L. X. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128782
Birth Cohort Effects in Adults Associated With Influenza A(H1N1)pdm09 Vaccine Effectiveness
Liu, F., Gross, F. L., Li, Z., House, S. L., Curley, T., Saade, E., Albar, Z., Zimmerman, R. K., Nowalk, M. P., Gaglani, M., et al. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag294
Self-citation
Human vaccine responses regulated by parallel cytokine pathways
Chen, G., Guo, J., Heath, J. E., Prestwood, T. R., Kwon, W. J., Smith, A. R., Nguyen, T. T., Kathuria, K. R., Sola, E., Sangaré, A., et al. (2026) · Nature Immunology · doi:10.1038/s41590-026-02547-x · Cited by 1
Influenza Viruses
Treanor, J. J. (2026) · Springer eBooks · doi:10.1007/978-1-4939-9544-8_19-3
Self-citation
State-of-the-art of the high dose influenza vaccine in Spain
Sanz-Muñoz, I., Avellà, J. M. F., Barroso-Santos, P. J., & Eiros, J. M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1843611
High-Dose Influenza Vaccination in Mexican Adults Aged 60 Years and Older.
Martin, R., Galván‐Oseguera, H., Alcocer, L., Palomo‐Piñón, S., Muñoz, E. G. C., Muñoz, J. M., Diaz, E., Mendoza, A. C., & Álvarez‐López, H. (2026) · Annals of Clinical Hypertension · doi:10.29328/journal.ach.1001043
Post-vaccination expansion of extrafollicular Th10 and regulatory Tfr cells distinguishes strong from weak influenza vaccine responses in older adultsPreprint
Mahajan, A. S., Ravichandran, S., Marcheş, R., Yazıcı, Y. Y., Nelson, S., Aydillo, T., Kshitija, K., Rojo-Fernandez, A., Nehar-Belaid, D., Kenyon‐Pesce, L., et al. (2026) · medRxiv · doi:10.64898/2026.07.02.26357118
Epidemiology, pathogenesis, and clinical defense strategies against autumn-winter respiratory diseases in the elderly: a focus on China and Asia
Wei, Z. H. A. O., & Yan, S. (2026) · Minerva Respiratory Medicine · doi:10.23736/s2784-8477.26.02256-4
Trends in Influenza-Associated Lower Respiratory Tract Infection Burden and Influenza Vaccination Coverage among Adults Aged ≥55 Years in China, 1990–2023Preprint
liu, M., & Chen, R. (2026) · medRxiv · doi:10.64898/2026.07.11.26357807
Expanding enhanced influenza vaccines programs for adults aged ≥65 in the Nordic region predicted to improve public health and health system resilience
Grootendorst, A., Paludan‐Müller, A. S., Madsen, K., Støvring, H., Nilsson, A., & Mould-Quevedo, J. F. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128934
Vaccines in the Golden Years
Talbot, H. K. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag382
Self-citation
Influenza Vaccination in Dialysis
Hsu, C. M., & Miskulin, D. C. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001185
Prevención cardiovascular integral: el papel de la vacunación en el adulto mayor con enfermedad cardiovascular. Documento de consenso de expertos
Bonanad, C., Alfaro, R., Morán-Bayón, Á., Cainzos‐Achirica, M., García‐Lledó, A., Raposeiras‐Roubín, S., Vivas, D., Freixa‐Pamias, R., Mora, J., Martín-Toro, M. A., et al. (2026) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2026.102819
A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes
Pardo-Seco, J., Rodríguez-Tenreiro-Sánchez, C., Giné-Vázquez, I., Mallah, N., Mirás‐Carballal, S., Piñeiro-Sotelo, M., Cribeiro-González, M., Pájaro, M. C., González‐Pérez, J., Calle, I. R., et al. (2026) · Clinical Infectious Diseases · doi:10.1093/cid/ciag466
A Randomized, Double-Blind Clinical Trial of One vs Two Doses of High-Dose Influenza Vaccine in Solid Organ Transplant Recipients
Escandón-Vargas, K., Tang, S. Q., Forschmiedt, J., Low, K., Lin, B. C., Wang, J. L., Castro, M., Narpala, S., Serebryannyy, L., Anderson, J. L., et al. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag494
Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults
Liu, Z., Zhang, L., & Jiang, M. (2026) · New England Journal of Medicine · doi:10.1056/nejmc2607826
Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire
Chen, H., Zhang, Z., Wen, Z., Yang, Z., Li, L., Wang, S., Gao, Q., Liu, H., Liu, L., & Chen, Y. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115262
Comparative effectiveness of influenza vaccination dosing strategies for cardiovascular protection: A systematic review and network meta-analysis of randomized controlled trials
Hon, J. J., Aikawa, T., Biering‐Sørensen, T., Crouch, E., Iwagami, M., Slipczuk, L. N., Briasoulis, Α., Wiley, J., Hosseini, K., Bhatt, D. L., et al. (2026) · American Heart Journal · doi:10.1016/j.ahj.2026.107591
What Antibody Repertoires See: Structural and Immunogenetic Insights Into Influenza A Virus Hemagglutinin Recognition
Bonnettaz, B., & Bajic, G. (2026) · Immunological Reviews · doi:10.1111/imr.70176
Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial
Essink, B. J., Vermeulen, W., Andrade, C., Mazur, M., de Rooij, R., Heijnen, E., Casula, D., 邢若雨, Piedrahita-Tovar, M., Garner, V., et al. (2026) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(26)00410-x
mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety
Domnich, A., & Orsi, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1965512
Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2
Espersen, C., Johansen, N. D., Modin, D., Janstrup, K. H., Loiacono, M. M., Harris, R. C., Huang, Y., Larsen, C. S., Larsen, L., Wiese, L., et al. (2026) · The Lancet Healthy Longevity · doi:10.1016/j.lanhl.2026.100894
Protection Before Day One: advancing broadly protective seasonal influenza vaccines with pandemic coverage
Jayashankar, L., DeGrace, M., Treanor, J. J., Swanson, N. J., Donabedian, A. M., & Lee, S. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.129188
Self-citation
Assessing CD8 + T cell cross‐reactivity to influenza A, B and C virus‐derived peptides presented by HLA‐B*18:01
Murdolo, L. D., Leong, S. L., Maddumage, J. C., D'Orsogna, L. J. A., Chatzileontiadou, D. S. M., Grant, E. J., & Gras, S. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70123
Humoral Immunogenicity of mRNA-1010, an mRNA-based Seasonal Influenza Vaccine, in Adults ≥50 Years
Leroux‐Roels, I., Malkin, E. M., Chen, H., Avanesov, A., Chen, R., Fidler, B., Das, R., & Wilson, E. M. P. (2026) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofag646
Vaccine Efficacy Trials
Roychoudhury, S., Koury, K., Pride, M., Kalina, W. V., Scully, I. L., Gruber, W. C., & Lockhart, S. P. (2026) · Springer eBooks · doi:10.1007/978-3-032-37993-1_4
Influenza Vaccination
Lingwood, D. (2025) · ImmPort · doi:10.21430/m3wbgcdkfd
Obese individuals show gene expression changes over time after influenza vaccination
Gresham, D. (2026) · ImmPort · doi:10.21430/m3orbfj9jj
High dose and standard dose fluzone vaccine titers
Handel, A. (2025) · ImmPort · doi:10.21430/m35rnpgho1
Single dose IIV vaccine expressing COBRA HA elicits broadly-reactive and long-lasting protection
Ross, T. (2025) · ImmPort · doi:10.21430/m3q2f40l9z
Exploring bias due to below-limit-of-detection in influenza vaccine antibody modeling
Shen, Y. (2026) · ImmPort · doi:10.21430/m36ro0ymma
Protection against influenza in elderly ferrets by adjuvanted influenza vaccine
Ross, T. (2026) · ImmPort · doi:10.21430/m3rclq5emc
Tcell Transcripts
Kennedy, R. (2024) · ImmPort · doi:10.21430/m3iim8aers
Recent trial evidence supports enhanced influenza vaccines for older adults: implications for Belgian practice
Callens, S. F. J., Peeters, M., & Laethem, Y. V. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2756252
Influenza Vaccination and Cardiovascular Protection: Current and Emerging Evidence in Primary and Secondary Prevention
Najafi, K., Hosseini, K., & Biering-Sørensen, T. (2026) · Journal of Gerontology and Geriatrics · doi:10.3390/jgg74040043

Authors: DiazGranados, C. A., Dunning, A. J., Kimmel, M., Kirby, D., Treanor, J., Collins, A., Pollak, R., Christoff, J., Earl, J., Landolfi, V., Martin, E., Gurunathan, S., Nathan, R., Greenberg, D. P., Tornieporth, N. G., Decker, M. D., & Talbot, H. K.
Affiliations: University of Pittsburgh (US)
University of Rochester (US)
PMG Research (US)
Martin Diagnostic Clinic (US)
Vanderbilt University (US)
Vanderbilt University Medical Center (US)
ORCID: Dunning, Andrew J.
Gurunathan, Sanjay
Decker, Michael D.
Talbot, H. Keipp
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2014-08-14
Volume: 371
Issue: 7
Pages: 635-645
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1315727
OpenAlex: W2168805652
Cited by: 876
References: 29
Citations by year: 2026: 76 · 2025: 89 · 2024: 60 · 2023: 78 · 2022: 68 · 2021: 95 · 2020: 80 · 2019: 78 · 2018: 68 · 2017: 65 · 2016: 65 · 2015: 42 · 2014: 10
FWCI: 45.92
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords: high-dose influenza vaccine, trivalent inactivated influenza vaccine, older adults, vaccine efficacy, laboratory-confirmed influenza, hemagglutination inhibition titers, immunogenicity, seroprotection, serious adverse events, influenza vaccination, 2011-2012 influenza season, 2012-2013 influenza season, antibody response
MeSH terms: Aged, Antibodies, Viral, Chronic Disease, Double-Blind Method, Female, Humans, Influenza, Human, Influenza Vaccines, Male, Orthomyxoviridae, Vaccines, Inactivated, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Efficacy of High-Dose versus Standard-Dose Influenza Vaccine in Older Adults

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks